Zepbound savings card, decoded

The confusion around Zepbound pricing almost always comes down to one variable: does your health plan formulary list Zepbound as a covered benefit for your specific diagnosis, or not? Everything else — the savings card tier you're eligible for, the amount you'll actually pay per fill, whether LillyDirect's cash pricing beats your insurance copay — flows from that single yes-or-no answer, not from your income, your BMI, or how badly you need the medication.

Eli Lilly runs two distinct versions of the Zepbound Savings Card, and picking the wrong one — or assuming you qualify for the headline $25 number — is the single biggest reason people get a surprise at the pharmacy counter. The card that gets advertised most heavily, the one printed on commercials and pharmacy flyers, is the "covered benefit" version: it only applies if your commercial insurance plan already covers Zepbound as a prescription benefit, even if you still owe a copay or coinsurance. For that group, the card exists purely to shrink the out-of-pocket copay down toward $25.

The second, less-publicized version is the "not covered" or "commercially insured, no coverage" card. This applies if you have commercial insurance, but that insurance specifically excludes GLP-1 or dual-agonist weight-management drugs from its formulary — a common exclusion, since many employer plans still carve out anti-obesity medications entirely. This version of the card doesn't get you to $25; it discounts the cash price down to a capped monthly and annual maximum, which in 2026 sits at up to $469 off per month and $3,283 off per year, applied against Lilly's list price.

A third path exists outside the savings card program altogether: LillyDirect, Lilly's own direct-to-consumer pharmacy, sells self-pay vials and single-patient-use pens at fixed cash prices with no insurance and no card required. For many people without drug coverage, this ends up cheaper in practice than the "not covered" savings card tier, especially at lower doses.

For commercially insured patients whose plan already lists Zepbound as a covered benefit, the card functions as a copay assistance program, not a discount off list price. It pays down whatever your insurer says you owe, down to a floor of $25 per fill — but only up to the monthly and annual caps above. If your plan's copay is already under $100, the card simply covers the difference down to $25 and you never hit the cap. If your plan's copay is high — some coinsurance structures leave patients owing $200–400 per fill even with "coverage" — the $100/month cap means you'll still owe a real balance out of pocket.

This is the change worth flagging for anyone who used the card in 2025: the monthly cap dropped from $150 to $100, and the annual cap dropped from $1,950 to $1,300. That's roughly a 33% cut in total available assistance for this tier, year over year. If your plan's copay structure hasn't changed but your realized savings feel smaller this year, this is almost certainly why — not an error at the pharmacy.

Enrollment happens once, at zepbound.lilly.com/savings or through the card offered by your prescriber's office, and then the discount applies automatically at the pharmacy counter each time the prescription is processed through insurance, as long as you're within the fill count and dollar caps for the year.

This tier exists for the specific, common situation where you do have private commercial insurance, but that plan's formulary carves out weight-management drugs as a category exclusion — meaning no amount of prior authorization or appeal changes the coverage decision, because the plan design itself doesn't include the drug class. In that case, the "not covered" savings card discounts Lilly's list price directly, rather than reducing an insurance copay, since there technically isn't one.

Because this version caps at 7 fills per year rather than 13, and the discount is measured against a higher list price rather than a copay, it's worth comparing directly against LillyDirect's flat self-pay pricing below before assuming the savings card is the better deal — for many people at the lower titration doses, it isn't.

LillyDirect is Lilly's own telehealth-linked pharmacy, and it sells Zepbound vials (and, depending on availability, single-patient-use pens) directly to self-pay patients — no insurance, no savings card, no prior authorization fight. This is the option for people whose plan excludes the drug entirely, people who are uninsured, or people on Medicare or Medicaid who are locked out of the commercial savings card by federal rules.

The pricing is dose-dependent and rises as you climb the titration ladder, which matters when budgeting: someone starting at 2.5mg pays notably less than someone who has titrated up to 10mg or 15mg. The 45-day refill window on maintenance doses (7.5mg and above) is a real constraint — if you let a refill lapse past that window, LillyDirect's system may not honor the lower maintenance-tier price on the next order, so timing refills matters as much as remembering the dose itself.

For many uninsured or excluded patients, running the numbers against the "not covered" savings card tier above is worth doing explicitly: at the 2.5mg starter dose, LillyDirect's $299 frequently beats the discounted list price under the savings card; at higher doses the gap narrows or can flip, depending on your plan's specific list price and discount structure that year.

One detail that trips people up: LillyDirect requires an active prescription from a licensed provider, which can come from your existing prescriber or from a telehealth consultation offered through the LillyDirect platform itself if you don't already have one. Either way, the prescription still has to reflect a clinically appropriate indication — LillyDirect isn't a way around needing a valid prescription, only a way around needing insurance to fill it.

The commercial savings card — either version — is unavailable to anyone enrolled in a federal or state healthcare program: Medicare Part D, Medicare Advantage, Medicaid, TRICARE, and VA benefits are all excluded by federal anti-kickback statute rules that apply to manufacturer copay assistance programs generally, not something specific to Lilly or Zepbound. Massachusetts residents are excluded under a separate state law restricting copay coupon programs regardless of insurance type.

None of this affects eligibility for LillyDirect self-pay pricing, which has no insurance-status restriction — it's a straightforward cash price available to anyone, including people in the excluded groups above. It's also, for many Medicare beneficiaries without Part D coverage for the drug, the only realistic path to obtaining Zepbound at a predictable monthly cost.

Enrollment for the covered-benefit savings card takes a few minutes and doesn't require your prescriber to do anything extra beyond writing the prescription. Go to zepbound.lilly.com/savings, confirm you're a US or Puerto Rico resident aged 18 or older, and answer the eligibility screening questions — primarily whether you have commercial (not government) insurance and whether that plan covers Zepbound. The site will route you to the correct version of the card based on your answers and issue a card number or downloadable card image immediately.

Bring that card number to the pharmacy along with your prescription, or have your pharmacy link it electronically if your prescriber's e-prescribing system supports it — many major chains do this automatically once you're enrolled and your insurance is on file. The discount then applies at the point of sale; you should never need to pay full price and seek reimbursement afterward, which is a red flag for scam savings programs unaffiliated with Lilly.

Re-enrollment isn't automatic across calendar years. Because the fill counts and dollar caps reset on January 1, and because Lilly can adjust the terms (as it did between 2025 and 2026), it's worth re-confirming your card is still active and re-reading the current terms at the start of each year rather than assuming last year's card details still apply unchanged.

The most common expensive mistake is assuming the $25 headline price applies universally. It's specific to the covered-benefit tier, and even within that tier it's a floor, not a guarantee — if your plan's copay is already below $25 for some reason, you simply pay the lower amount; the card doesn't pay you extra. People who see "$25" advertised and don't check which tier they fall into are the ones most likely to be surprised at the register.

A second common mistake is letting a LillyDirect maintenance-dose refill lapse past the 45-day window, which can bump the price back up for that order. Setting a recurring reminder a few days before the window closes is a simple fix, and it's one of the more mechanical, easy-to-automate parts of managing the cost of ongoing treatment.

A third mistake, more of a missed opportunity than an error, is not comparing the "not covered" savings card tier against LillyDirect self-pay pricing before defaulting to whichever one a pharmacist or online source happens to mention first. Because the math depends on your specific dose and your plan's list price that year, the cheaper option can flip between the two — it's worth pricing both out explicitly, especially early in titration when doses (and therefore price gaps) are smaller.

Finally, some people discover late that their pharmacy simply isn't enrolled in Lilly's savings card processing network, particularly smaller independent pharmacies. Calling ahead to confirm before showing up with a new prescription avoids an unnecessary trip and a full-price transaction you'd then have to sort out after the fact.

It's worth understanding why some employer plans exclude Zepbound in the first place, because it changes what — if anything — is worth appealing. Anti-obesity medications as a drug class have historically been carved out of many employer-sponsored plans for straightforward cost-control reasons: GLP-1 and dual-agonist drugs are expensive at list price, adoption has grown quickly, and a plan sponsor renewing its benefits package for the coming year often faces a direct choice between covering the drug class broadly or holding premium increases down for the entire employee population.

This is a plan-design decision made by the employer or plan sponsor, not a clinical judgment about whether the medication is appropriate for you specifically — which is an important distinction, because it means a formulary exclusion usually can't be overturned through a medical necessity appeal the way a coverage denial for a covered drug sometimes can. If your plan's formulary excludes the entire weight-management drug class, your realistic options are the "not covered" savings card tier, LillyDirect self-pay, or raising the coverage gap with your employer's HR or benefits team during the next open enrollment period — some employers do add the coverage in response to employee demand.

By contrast, if your plan does cover Zepbound but a specific claim was denied — for example, over documentation of a qualifying BMI or comorbidity — that's a different situation with a real appeals process through your insurer, separate from anything the savings card can address. The card assumes coverage exists; it doesn't create it.